|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
2
|
Black PC and Dinney CP: Bladder cancer
angiogenesis and metastasis - translation from murine model to
clinical trial. Cancer Metastasis Rev. 26:623–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matrisian LM: Metalloproteinases and their
inhibitors in matrix remodeling. Trends Genet. 6:121–125. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liotta LA: Tumor invasion and
metastasis-role of extracellular matrix: Rhoads Memorial Award
Lecture. Cancer Res. 46:1–7. 1986.PubMed/NCBI
|
|
5
|
Sier CF, Casetta G, Verheijen JH, et al:
Enhanced urinary gelatinase activities (matrix metalloproteinases 2
and 9) are associated with early-stage bladder carcinoma: a
comparison with clinically used tumor markers. Clin Cancer Res.
6:2333–2340. 2000.
|
|
6
|
Davies B, Waxman J, Wasan H, et al: Levels
of matrix metalloproteases in bladder cancer correlate with tumor
grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
7
|
Nutt JE, Durkan GC, Mellon JK and Lunec J:
Matrix metalloproteinases (MMPs) in bladder cancer: the induction
of MMP9 by epidermal growth factor and its detection in urine. BJU
Int. 91:99–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moses MA, Wiederschain D, Loughlin KR,
Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix
metalloproteinases in urine of cancer patients. Cancer Res.
58:1395–1399. 1998.PubMed/NCBI
|
|
9
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Urinary gelatinase activities (matrix metalloproteinases
2 and 9) in human bladder tumors. Oncol Rep. 15:1321–1326.
2006.PubMed/NCBI
|
|
10
|
Kumar B, Koul S, Petersen J, et al: p38
mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion
of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer
Res. 70:832–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mook OR, Frederiks WM and Van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
12
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Busti C, Falcinelli E, Momi S and Gresele
P: Matrix metalloproteinases and peripheral arterial disease.
Intern Emerg Med. 5:13–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takatsu K and Nakajima H: IL-5 and
eosinophilia. Curr Opin Immunol. 20:288–294. 2008. View Article : Google Scholar
|
|
15
|
Adachi T and Alam R: The mechanism of IL-5
signal transduction. Am J Physiol. 275:C623–C633. 1998.PubMed/NCBI
|
|
16
|
Moon SK, Cha BY and Kim CH: ERK1/2
mediates TNF-alpha-induced matrix metalloproteinase-9 expression in
human vascular smooth muscle cells via the regulation of NF-kappaB
and AP-1: involvement of the ras dependent pathway. J Cell Physiol.
198:417–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu HK, Hirai H, Inamori K, Kitamura K and
Takaku F: Anti-tumor effects of interleukin-4 and interleukin-5
against mouse B cell lymphoma and possible mechanisms of their
action. Jpn J Cancer Res. 83:200–210. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masuda Y, Mita S, Sakamoto K, Ishiko T and
Ogawa M: Suppression of in vivo tumor growth by the transfection of
the interleukin-5 gene into colon tumor cells. Cancer Immunol
Immunother. 41:325–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tyagi P, Barclay D, Zamora R, et al: Urine
cytokines suggest an inflammatory response in the overactive
bladder: a pilot study. Int Urol Nephrol. 42:629–635. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Michaud DS: Chronic inflammation and
bladder cancer. Urol Oncol. 25:260–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dinney CP, Fishbeck R, Singh RK, et al:
Isolation and characterization of metastatic variants from human
transitional cell carcinoma passaged by orthotopic implantation in
athymic nude mice. J Urol. 154:1532–1538. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mian BM, Dinney CP, Bermejo CE, et al:
Fully human anti-interleukin 8 antibody inhibits tumor growth in
orthotopic bladder cancer xenografts via down-regulation of matrix
metalloproteases and nuclear factor-kappaB. Clin Cancer Res.
9:3167–3175. 2003.PubMed/NCBI
|
|
24
|
Kader AK, Liu J, Shao L, et al: Matrix
metalloproteinase polymorphisms are associated with bladder cancer
invasiveness. Clin Cancer Res. 13:2614–2620. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee SJ, Park SS, Lee US, Kim WJ and Moon
SK: Signaling pathway for TNF-alpha-induced MMP-9 expression:
mediation through p38 MAP kinase, and inhibition by anti-cancer
molecule magnolol in human urinary bladder cancer 5637 cells. Int
Immunopharmacol. 8:1821–1826. 2008. View Article : Google Scholar
|
|
26
|
Cho A, Graves J and Reidy MA:
Mitogen-activated protein kinases mediate matrix
metalloproteinase-9 expression in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 20:2527–2532. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wiehler S, Cuvelier SL, Chakrabarti S and
Patel KD: p38 MAP kinase regulates rapid matrix metalloproteinase-9
release from eosinophils. Biochem Biophys Res Commun. 315:463–470.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao J, Xiong S, Klos K, et al: Multiple
signaling pathways involved in activation of matrix
metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast
cancer cells. Oncogene. 20:8066–8074. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Genersch E, Hayess K, Neuenfeld Y and
Haller H: Sustained ERK phosphorylation is necessary but not
sufficient for MMP-9 regulation in endothelial cells: involvement
of Ras-dependent and -independent pathways. J Cell Sci.
113:4319–4330. 2003.PubMed/NCBI
|
|
30
|
Lee SJ, Park SS, Cho YH, et al: Activation
of matrix metalloproteinase-9 by TNF-alpha in human urinary bladder
cancer HT1376 cells: the role of MAP kinase signaling pathways.
Oncol Rep. 19:1007–1013. 2008.PubMed/NCBI
|
|
31
|
Chang HR, Huang HP, Kao YL, et al: The
suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic
Ras/RhoA induced invasion/migration of human bladder cancer TSGH
cells. Chem Biol Interact. 183:172–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takaki S, Murata Y, Kitamura T, Miyajima
A, Tominaga A and Takatsu K: Reconstitution of the functional
receptors for murine and human interleukin 5. J Exp Med.
177:1523–1529. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dranoff G: Cytokines in cancer
pathogenesis and cancer therapy. Nat Rev Cancer. 4:12–22. 2004.
View Article : Google Scholar
|
